# PegBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pegbio-co

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.pegbio.com/
- Total disclosed funding: $3.1M
- Latest round: Series D (Jun 1, 2014)
- Investors on record: 3

## About

Founded in 2008 and based in Suzhou, China, PegBio Co., Ltd. is a biopharmaceutical company that focuses on the research and development of innovative drugs for diabetes and obesity.

Based in China and established in 2008 as Suzhou PegBio Medical Co., Ltd., later was converted into a joint stock company in 2020. In 2025, the company changed its name to Hangzhou PegBio Medical Co., Ltd. upon redomiciling its registered office to Hangzhou. In May 2025, the company completed its initial public offering on the Hong Kong Stock Exchange.

PegBio's drug pipeline focus on the development of long-acting peptide drugs for metabolic and endocrine diseases, including PB-119, PB-718, PB-401 and others. 

The company generates revenue mainly from commercialization of drugs and licensing agreements for pipeline products.

With funds raised from the IPO, the company plans to advance clinical trials and support further R&D to develop overseas commercialization strategies.

## Funding rounds

- Series D, Jun 1, 2014, $1M — Legend Star
- Series C, May 1, 2011, $1.1M — Oriza Holdings
- Series B, Mar 1, 2011 — Mingxin Capital
- Series A, Jan 1, 2011, $1M — Legend Star

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A, Series D
- Mingxin Capital (https://capitalatlas.ai/funds/mingxin-capital) — Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C